KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC)

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Casadei Gardini, Andrea ^a   Capelli, Laura ^a   Ulivi, Paola ^a   Giannini, Massimo ^b   Freier, Eva ^c   Tamberi, Stefano ^c   Scarpi, Emanuela ^a   Passardi, Alassandro ^a   Zoli, Wainer ^a   Ragazzini, Angela ^a   Amadori, Dino ^a   Frassinet, Giovanni Luca ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b Macerata Hospital   (Italy)

^c Degli Infermi Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; DNA; DRUG THERAPY; FLUOROURACIL; K RAS PROTEIN; KRAS PROTEIN, HUMAN; MITOMYCIN; ONCOPROTEIN; PARAFFIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; RAS PROTEIN;

ADULT; AGED; ANUS CARCINOMA; ANUS NEOPLASMS; ARTICLE; BRAF GENE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CARCINOMA, SQUAMOUS CELL; CLINICAL ARTICLE; CLINICAL FEATURE; COMPLICATION; DISEASE ASSOCIATION; DNA EXTRACTION; EXON; FEMALE; FOLLOW UP; GAMMA RADIATION; GENE MUTATION; GENETICS; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 6; HUMAN TISSUE; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; MUTATION; NERVE FIBER; NUCLEOTIDE SEQUENCE; ONCOGENE K RAS; OVERALL SURVIVAL; PAPILLOMAVIRUS INFECTION; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; PIK3CA GENE; PROGRESSION FREE SURVIVAL; PYROSEQUENCING; RETROSPECTIVE STUDY; SQUAMOUS CELL ANAL CARCINOMA; SQUAMOUS CELL CARCINOMA; THERAPY;

AGED; ANTINEOPLASTIC AGENTS; ANUS NEOPLASMS; AXONS; CARCINOMA, SQUAMOUS CELL; COMPLICATIONS; DNA MUTATIONAL ANALYSIS; FEMALE; FLUOROURACIL; GAMMA RAYS; GENETICS; HUMAN PAPILLOMAVIRUS 16; HUMANS; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; MITOMYCIN; MUTATION; NEOPLASM STAGING; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RETROSPECTIVE STUDIES; THERAPEUTIC USE; THERAPY;

EID: 84898670648     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0092071     Document Type: Article

References (22)

1. Škamperle M, Kocjan BJ, Maver PJ, Seme K, Poljak M (2013) Human papillomavirus (HPV) prevalence and HPV type distribution in cervical, vulvar, and anal cancers in Central and Eastern Europe. Acta Dermatovenerol Alp Panonica Adriat 22: 1-5.
2. Barmettler H, Komminoth P, Schmid M, Duerr D (2012) Efficacy of cetuximab in combination with FOLFIRI in a patient with KRAS wild-type metastatic anal cancer. Case Rep Oncol 5: 428-433.
3. Bamba T, Suda T, Nakano M, Terashima T, Umezu H (2012) Pathologically complete response for unresectable stage IV rectal cancer using systemic chemotherapy with panitumumab - a case report. Gan To Kagaku Ryoho 39: 311-315.
4. Lukan N, Ströbel P, Willer A, Kripp M, Dinter D, et al. (2009) Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status. Oncology 77: 293-299.
5. Paliga A, Onerheim R, Gologan A, Chong G, Spatz A, et al. (2012) EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors? Br J cancer 107: 1864-1868.
6. Zampino MG, Magni E, Sonzogni A, Renne G (2009) K-ras status in squamous cell anal carcinoma (SCC): it's time for target-oriented treatment? Cancer Chemother Pharmacol 65: 197-199.
7. Van Damme N, Deron P, Van Roy N, Demetter P, Bols A, et al.(2010) Epidermal Growth Factor Receptor and K-RAS status in two cohorts of squamous cell carcinomas. BMC Cancer 10: 189.
8. Ulivi P, Capelli L, Valgiusti M, Zoli W, Scarpi E, et al. (2012) Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: a single center study. J Transl Med 10: 87.
9. Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, et al. (2010) AJCC Cancer Staging Manual (7th Edition). New York: Springer.
10. Kaplan EL, Meier P (2005) Non-parametric estimation from incomplete observation. J Am Stat Assoc 24: 341-358.
11. Lawkess JS (1982) Statistical models and methods for life-time data. New York: John Wiley and Sons 10: 316-317.
12. Cox DR (1972) Regression models and life tables. J Royal Stat Soc 34: 187-220.
13. Das P, Bhatia S, Eng C, Ajani JA, Skibber JM, et al. (2007) Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys 68: 794-800. (Pubitemid 46818735)
14. Yhim HY, Lee NR, Song EK, Kwak JY, Lee ST, et al. (2011) The prognostic significance of tumour human papillomavirus status for patients with anal squamous cell carcinoma treated with combined chemoradiotherapy. Int J Cancer 129: 1752-1760.
15. Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, et al. (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992-3995.
16. Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, Molinari F, De Dosso S, et al. (2009) Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One 4: e7287.
17. Bruckman KC, Schönleben F, Qiu W, Woo VL, Su GH (2010) Mutational analyses of the BRAF, KRAS, and PIK3CA genes in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 110: 632-637.
18. Pochylski T, Kwaśniewska A (2003) Absence of point mutation in codons 12 and 13 of K-RAS oncogene in HPV-associated high grade dysplasia and squamous cell cervical carcinoma. Eur J Obstet Gynecol Reprod Biol 111: 68-73. (Pubitemid 37235950)
19. Lui VW, Hedberg ML, Li H, Vangara BS, Pendleton K, et al. (2013) Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers. Cancer Discov 3: 761-769.
20. McIntyre JB, Wu JS, Craighead PS, Phan T, Köbel M, et al. (2013) PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy. Gynecol Oncol 128: 409-414.
21. Olivatto LO, Meton F, Bezerra M, Cardoso A, Araujo CM, et al. (2006) Phase I study of cetuximab (CET) in combination with 5-fluorouracil (5-FU), cisplatin (CP), and radiotherapy (RT) in patients with locally advanced squamous cell anal carcinoma (LAAC). J Clin Oncol (suppl. 243) (abstr. 4609).
22. Deutsch E, Lemanski C, Pignon JP, Levy A, Delarochefordiere A, et al. (2013) Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial. Ann Oncol 2013: 24:2834-2838